Approval · Notice of Compliance 10633 · 2009
NU-RISPERIDONE: Notice of Compliance 10633
Issued October 4, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10633
- Date
- October 4, 2009
- Company
- Nu-Pharm IncVaughan, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Antipsychotic agent
- Canadian reference product
- RISPERDAL (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NU-RISPERIDONE | 02334372 | Cancelled (Unreturned Annual) |
| NU-RISPERIDONE | 02334380 | Cancelled (Unreturned Annual) |
| NU-RISPERIDONE | 02334399 | Cancelled (Unreturned Annual) |
| NU-RISPERIDONE | 02334402 | Cancelled (Unreturned Annual) |
| NU-RISPERIDONE | 02334410 | Cancelled (Unreturned Annual) |
| NU-RISPERIDONE | 02334429 | Cancelled (Unreturned Annual) |
Medicinal ingredients
- RISPERIDONE 0.25 MG per TAB
- RISPERIDONE 0.5 MG per TAB
- RISPERIDONE 1 MG per TAB
- RISPERIDONE 2 MG per TAB
- RISPERIDONE 3 MG per TAB
- RISPERIDONE 4 MG per TAB